A clinical indicator-based prognostic model predicting treatment outcomes of pulmonary tuberculosis: a prospective cohort study

Author:

Zhan Mengyao,Xue Hao,Wang Yuting,Wu Zhuchao,Wen Qin,Shi Xinling,Wang Jianming

Abstract

Abstract Objectives Identifying prognostic factors helps optimize the treatment regimen and promote favorable outcomes. We conducted a prospective cohort study on patients with pulmonary tuberculosis to construct a clinical indicator-based model and estimate its performance. Methods We performed a two-stage study by recruiting 346 pulmonary tuberculosis patients diagnosed between 2016 and 2018 in Dafeng city as the training cohort and 132 patients diagnosed between 2018 and 2019 in Nanjing city as the external validation population. We generated a risk score based on blood and biochemistry examination indicators by the least absolute shrinkage and selection operator (LASSO) Cox regression. Univariate and multivariate Cox regression models were used to assess the risk score, and the strength of association was expressed as the hazard ratio (HR) and 95% confidence interval (CI). We plotted the receiver operating characteristic (ROC) curve and calculated the area under the curve (AUC). Internal validation was conducted by 10-fold cross-validation. Results Ten significant indicators (PLT, PCV, LYMPH, MONO%, NEUT, NEUT%, TBTL, ALT, UA, and Cys-C) were selected to generate the risk score. Clinical indicator-based score (HR: 10.018, 95% CI: 4.904–20.468, P < 0.001), symptom-based score (HR: 1.356, 95% CI: 1.079–1.704, P = 0.009), pulmonary cavity (HR: 0.242, 95% CI: 0.087–0.674, P = 0.007), treatment history (HR: 2.810, 95% CI: 1.137–6.948, P = 0.025), and tobacco smoking (HR: 2.499, 95% CI: 1.097–5.691, P = 0.029) were significantly related to the treatment outcomes. The AUC was 0.766 (95% CI: 0.649–0.863) in the training cohort and 0.796 (95% CI: 0.630–0.928) in the validation dataset. Conclusion In addition to the traditional predictive factors, the clinical indicator-based risk score determined in this study has a good prediction effect on the prognosis of tuberculosis.

Funder

Yancheng Medical Science and Technology Development Program

National Natural Science Foundation of China

Medical Research Project of Jiangsu Health Commission

Nanjing Major Science and Technology Project

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Reference37 articles.

1. WHO. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.

2. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morbidity and mortality weekly report. 2018;67(25):723–6.

3. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports. 2000, 49(RR-6):1–51.

4. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in south african mineworkers. Lancet. 2001;358(9294):1687–93.

5. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J tuberculosis lung disease: official J Int Union against Tuberculosis Lung Disease. 2007;11(8):828–37.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3